Heart failure patients get Dual-Drug hope
NCT ID NCT06520891
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing whether taking a statin (atorvastatin) together with an SGLT2 inhibitor (dapagliflozin) helps people with ischemic heart failure. Researchers will measure cholesterol levels and other lab tests in 90 participants. The goal is to see if the combination works better than either drug alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atorvastatin (statin) and dapagliflozin (SGLT2i)
- What this could lead to
- If it works, this could show that taking both drugs together helps manage cholesterol and heart health better than either alone.
- What could go wrong
- This is a small, early-phase study with only 90 participants, so results may not apply to everyone. The trial focuses on lab tests, not long-term outcomes like survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 2 DRUGS ARE STATIN AND SGLT2I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asmaa mohamed abdelkader
RECRUITINGAl Fayyum, Faiyum Governorate, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a higher dose of adenosine sharpen heart scans?
- Dental repair may boost heart and metabolic health
- Heart attack aftermath: new imaging method may spot hidden danger zones better than standard tests
- New stent design tested in thousands with complex heart blockages
- AR video may ease anxiety before heart catheterization
- New scan method could prevent unnecessary stents after heart attacks